Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2010

Uaprasert Noppacharn, Voorhees Peter M, Mackman Nigel, Key Nigel S

Abstract excerpt

Patients with multiple myeloma are at increased risk of venous thromboembolism (VTE) compared to the general population. The introduction of immunomodulatory agents, such as thalidomide and lenalidomide, substantially increases the incidence of VTE in multiple myeloma patients, especially when us...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Factor V
Share to Fibrinolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Mutation

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Share to Venous Thromboembolism

Source

Identifiers

PMID: 20385482
DOI: 10.1016/j.ejca.2010.03.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20385482-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.PMID 20385482Read ↗

A review of the venous thrombotic issues associated with multiple myeloma.Semantic proximity Read ↗

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.Semantic proximity Read ↗

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Semantic proximity Read ↗

Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.Semantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature reviewSemantic proximity Read ↗

Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma.Semantic proximity Read ↗

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Semantic proximity Read ↗

Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia.Semantic proximity Read ↗

Thrombotic microangiopathy associated with proteasome inhibitorsSemantic proximity Read ↗

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.Semantic proximity Read ↗

Adjuvant therapy in breast cancer and venous thromboembolism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.